|
Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia Clinical research trials and Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia. Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia clinical trial. Test subjects typically obtain the finest healthcare available for their Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia  Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
For Condition: Myelodysplastic Syndrome
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: This study will determine the safety and effectiveness of a combination of the immune-suppressing drugs antithymocyte globulin (ATG) and cyclosporine for treating myelodysplasia, a disorder of low blood cell counts. It will: 1) evaluate whether this drug combination can increase blood counts in patients and reduce their need for transfusions; 2) compare survival of patients who respond to ATG and cyclosporine treatment with those who do not respond; and 3) determine the side effects of the treatment. Myelodysplasia is thought to result from an immune system abnormality in which cells called lymphocytes attack the marrow's blood-forming cells. The resulting deficiencies of platelets and red and white blood cells cause anemia, susceptibility to infections, and easy bruising and bleeding. Various therapies, such as blood transfusions for anemia and bleeding, antibiotics for infection, chemotherapy and bone marrow transplantation are used to treat myelodysplasia, but all have disadvantages and some carry serious risks. Patients 18 years of age and older with myelodysplasia may be eligible for this study. Candidates will be screened with a physical examination and medical history, blood tests, chest X-ray, electrocardiogram and bone marrow biopsy (removal of a marrow sample from the hipbone for microscopic examination). For this procedure, the hip area is anesthetized and a special needle is used to draw marrow from the bone. Participants will be admitted to the NIH Clinical Center for the first 10 days of treatment and will then continue therapy on an outpatient basis. They will undergo the following tests and procedures: * Placement of central line-An intravenous (IV) catheter (flexible tube inserted into a vein) is placed in a large vein of the neck, chest or arm. Medicines are delivered through this line and blood samples are drawn from it. * ATG skin testing-ATG is injected under the skin to check for sensitization to horse serum, from which the drug is derived. * ATG treatment-Four doses of ATG are given through the IV line on each of 4 consecutive days. Prednisone is taken by mouth beginning the first day of ATG therapy and continuing for a total of 17 days. This drug is given to reduce the side effects of ATG, such as fever, skin rash and chills. * Cyclosporine treatment-Cyclosporine capsules are taken by mouth twice a day for at least 6 months. During hospitalization, blood will be drawn daily for blood counts and other tests. Upon the patient's discharge after 10 days, the referring physician will do blood tests weekly during the first month of treatment and then every 2 weeks for the rest of the time the patient is taking cyclosporine. Dosages of this drug may be adjusted depending on the test results. Patients will be evaluated at the NIH Clinical Center at 3-month intervals for the first year, then every 6 months for the next 3 years and then at yearly intervals. A blood sample will be drawn at each visit. Bone marrow biopsies will be done at 6-month intervals for the first 3 years after treatment.
Details: A growing body of laboratory and clinical evidence suggests that the cytopenia of MDS is at least partly a result of cytotoxic T cell activity. Treatments to abrogate T cell activity such as anti-thymocyte globulin alone and cyclosporine alone have demonstrated varying degrees of success in alleviating the cytopenia of MDS. A response to such therapy in MDS is associated with improved survival. Experience with aplastic anemia suggests that the combination of these two agents should be more effective in suppressing cytotoxic T cell activity and alleviating cytopenia. This protocol proposes using the combination of antithymocyte globulin (ATG) and cyclosporine (CSA) to treat the cytopenia of MDS, in an effort to improve the response rate to immunosuppressive therapy in this disease.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: MDS of RA, RARS & RAEB sub-types Off all other treatments (except G-CSF, and transfusion support and related medications) for at least four weeks. G-CSF can be used before, during and after the protocol treatment for patients with documented neutropenia (less than 500/uL) as long as they meet the criteria for anemia and/or thrombocytopenia as stated above. ECOG performance status of 2 or less EXCLUSION CRITERIA: MDS of FAB sub-group chronic myelomonocytic leukemia (CMML) Transformation to acute leukemia (FAB sub-group RAEB-T, ie., greater than 20% blasts in marrow aspirate) Hypoplastic marrow without one major or two minor criteria Treatment with growth factors (except for G-SCF) or cyclosporine within 4 weeks prior to entry to protocol ECOG performance status of greater than 2 Active uncontrolled infection Current pregnancy, or unwilling to take oral contraceptives if of childbearing potential Patients for whom bone marrow transplant is indicated as standard therapy (age less than fifty-five with a fully-matched sibling donor) Age less than18 years Not able to give informed consent HIV positive patients Active malignant disease (excluding basal cell carcinoma) Serum creatinine greater than 2mg/dl Patients who are moribund or patients with concurrent hepatic, renal, cardiac, metabolic, or any disease of such severity that death within 3 months is likely Low predicted probability of response
Total Enrollment: 42
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 000169; 00-H-0169
Study Start Date: June 29, 2000
Record last reviewed: June 20, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005937
Other Myelodysplastic Syndrome Studies:
1. Phase III Trial of decitabine versus supportive care in adults with advanced-stage MDS
2. Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
3. Clofarabine combinations in relapsed/refractory AML, MDS and myeloid blast phase CML
4. Collection of Blood and Bone Marrow from Normal Volunteers and Patients for Research Purposes
5. Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
Related Studies:
Other Myelodysplastic Syndrome Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
|
|
|
|
|
|
|
|
